Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population
by Global PharmacovigilanceTrying to identify genetic biomarkers of nevirapine hypersensitivity.
Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool
by Global PharmacovigilanceWhilst there is much focus on detecting and monitoring safety in both research and clinical practice, there is far less information on the issue of avoiding them. As such, a new adverse drug reaction avoidability assessment tool was developed and tested by the researchers of this paper. Developed in a paediatric research setting, it is hoped that its use could be extended to a variety of settings.
PAPER - an assessment of how adverse events from clinical trials are reported in published papers
by Global PharmacovigilanceA recently published paper in PLOS Medicine has investigated how adverse event data from clinical trials are summarised and consequently reported in published papers.
ACT Consortium – Pharmacovigilance activities and outputs
by Global PharmacovigilanceAlthough there is now a good research pipeline of antimalarial drugs in response to the rapid spread of drug resistant malaria, there is very little evidence on how these drugs should best be deployed. The ACT Consortium is a global research partnership of a number of eminent public health and academic institutions in Africa, Asia, Europe and the United States where our projects' Principal Investigators are based. Research focuses around four major themes relating to artemisinin-based combination therapies (ACTs), the first-line treatment recommended by the World Health Organisation for malaria - in Africa and Asia: targeting, access, quality and safety. Including safety as a theme was important as, despite the wide scale use of ACTs, little is known about their long-term effects and their use in vulnerable populations, such as those co-infected with HIV. Moreover, it is clear that there is a need to work towards the pooling of safety data from multiple studies to understand uncommon adverse drug reactions that may not be detected by individual studies.